Kailera Therapeutics, Inc. (NASDAQ:KLRA) Receives Average Rating of “Buy” from Analysts

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA) have been assigned a consensus rating of “Buy” from the seven brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $42.75.

A number of analysts recently weighed in on KLRA shares. Zacks Research upgraded shares of Kailera Therapeutics to a “hold” rating in a report on Wednesday, May 13th. William Blair assumed coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “outperform” rating on the stock. Leerink Partners assumed coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They set an “outperform” rating and a $36.00 price objective for the company. Evercore began coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They set an “outperform” rating for the company. Finally, Wall Street Zen lowered Kailera Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th.

Kailera Therapeutics Stock Up 1.7%

Shares of NASDAQ KLRA opened at $17.69 on Friday. Kailera Therapeutics has a twelve month low of $16.76 and a twelve month high of $28.23. The firm has a market cap of $2.29 billion and a P/E ratio of -0.00. The firm has a 50-day simple moving average of $20.47.

Kailera Therapeutics (NASDAQ:KLRA) last announced its quarterly earnings data on Tuesday, May 26th. The company reported ($3,650.00) earnings per share (EPS) for the quarter.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.